A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2016
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vinorelbine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms VELVET
- Sponsors Roche
- 01 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Oct 2015 Planned End Date changed from 1 Jun 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov.
- 01 Oct 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov.